Post by Bavarian Nordic

Our Q1 2026 results are out – and they confirm the strength of our business. 👇 🌍 Travel Health delivered strong growth, driven by sustained demand and our continued focus on organic growth in existing markets 🛡️ Public Preparedness performed in line with expectations in a more normalized environment following years of outbreak‑driven demand Within Travel Health, our chikungunya vaccine continues to gain traction, while our rabies vaccine remains a key growth driver. 📈 Following a new contract from the US government for the production and supply of smallpox vaccines, we have upgraded our full‑year guidance to DKK 5,500–5,700 million and an EBITDA margin of approximately 28%. We are proud of the trust placed in our company and our vaccines. That trust from customers, governments and partners reflects the continued need for our vaccines – and the role we play in helping safeguard communities against emerging threats. Explore the key Q1 2026 figures in the infographic below. #News #Q1 #Interimreport